论文部分内容阅读
目的:通过检测鼻咽癌患者治疗前血清中TGF-β1的浓度,探讨其与鼻咽癌患者临床特征及预后的关系。方法:采用酶联免疫吸附(ELISA)实验方法,检测初治156例鼻咽癌患者治疗前血清中的TGF-β1表达水平,分析血清中TGF-β1浓度对鼻咽癌预后的影响。结果:156例鼻咽癌患者治疗前血清TGF-β1的平均浓度明显高于健康对照组〔(60.24±28.33)ng/mLvs(30.14±14.14)ng/mL〕。进而以52.11 ng/mL为节点,将156例鼻咽癌患者分成TGF-β1高、低浓度组,两组间3年无转移生存率差异有统计学意义,P=0.000。Cox多因素回归结果显示,鼻咽癌患者治疗前血清中高浓度TGF-β1是总生存和无转移生存的不良预后因素,P均<0.001。结论:鼻咽癌患者治疗前血清中TGF-β1浓度可能成为预测鼻咽癌治疗后远处转移的分子指标之一。
Objective: To detect the serum concentration of TGF-β1 in patients with nasopharyngeal carcinoma before treatment to explore its relationship with the clinical features and prognosis of patients with nasopharyngeal carcinoma. Methods: The levels of TGF-β1 in serum of 156 nasopharyngeal carcinoma patients before treatment were detected by enzyme-linked immunosorbent assay (ELISA), and the effect of serum TGF-β1 on the prognosis of nasopharyngeal carcinoma was analyzed. Results: The average serum TGF-β1 level in 156 NPC patients before treatment was significantly higher than that in healthy controls [(60.24 ± 28.33) ng / mL vs (30.14 ± 14.14) ng / mL〕. Furthermore, 52.11 ng / mL was taken as the node to divide 156 NPC patients into high and low TGF-β1 group. There was significant difference in 3-year non-metastasis survival rate between the two groups (P = 0.000). Cox regression analysis showed that the high concentration of TGF-β1 in the serum of NPC patients before treatment was a poor prognostic factor for overall survival and metastasis-free survival (P <0.001). Conclusion: The serum levels of TGF-β1 in patients with nasopharyngeal carcinoma before treatment may be one of the molecular predictors of distant metastasis after the treatment of nasopharyngeal carcinoma.